Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Gift 5 articles to anyone you choose each month when you subscribe. Danish pharmaceutical giant Novo Nordisk says about 13 million Australians are living with obesity or are overweight ...

Novo Nordisk on Monday revealed data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares ...

Novo Nordisk is planning to open an artificial intelligence (AI) research facility in London, UK, as part of a drive to place the technology at the heart of its drug discovery operations.

Novo Nordisk has agreed its second acquisition in the space of a month of a biotech in the obesity category, snapping up fellow Danish company Embark Biotech for €15 million (around $16 million ...

Mens Novo Nordisk tjener milliarder på fedmemedicin, bliver medicinalgigantens amerikanske medarbejderes pension investeret i junkfood Mens Novo Nordisk tjener styrtende på vægttabsmedicin ...

The table below is a review of notable updates that occurred in February 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...